Pipeline

FIRST-IN-CLASS NCE ENB003 AND ENB001:

Potential Synergy with Multiple Immuno-oncology Platforms

ENLARGE GRAPHIC

MECHANISM OF ACTION

ENLARGE GRAPHIC

BQ788:
PARENT COMPOUND

  • Off-patent research tool for cardiovascular disease
  • Established safety profile in >30 clinical studies (administered to 400+ patients)
  • Robust pre-clinical proof of concept across multiple cancers
  • Converts tumor infiltrating lymphocytes (TIL)- tumors to TIL+
  • Enhances immunotherapy efficacy
  • Orphan drug designation for melanoma awarded by FDA to ENB
  • Low solubility, rapid plasma clearance

ENB003

  • Deuterium exchanged NCE derivative of BQ788
  • COM issued 2019
  • Enhanced pharmacodynamics profile
  • Launch in initial target indications (non-central nervous system, CNS)
  • Orphan Drug designation for melanoma awarded by FDA
  • Currently being evaluated in clinical trials in collaboration with Merck

ENB001

  • Nanoparticle formulation of BQ788-accelerated clinical path
  • Strong IP- COM 2015
  • ⇡ Solubility
    ↓ Plasma clearance
  • Being developed to cross the blood-brain-barrier for CNS malignancy

ENB’s Advantage

ENLARGE GRAPHIC

Get in touch

Contact Us